Provided by Tiger Trade Technology Pte. Ltd.

Sangamo Therapeutics Inc

0.3782
-0.0179-4.52%
Post-market: 0.38670.0085+2.25%18:18 EDT
Volume:4.05M
Turnover:1.56M
Market Cap:140.69M
PE:-0.85
High:0.4096
Open:0.3955
Low:0.3779
Close:0.3961
52wk High:1.04
52wk Low:0.3450
Shares:372.00M
Float Shares:364.00M
Volume Ratio:1.29
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4450
EPS(LYR):-0.4856
ROE:-480.02%
ROA:-68.11%
PB:22.54
PE(LYR):-0.78

Loading ...

Sangamo Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
1 hour ago

Sangamo submits ST-920 BLA clinical and preclinical modules to FDA for Fabry disease accelerated approval review

Reuters
·
Mar 09

Sangamo Therapeutics Advances Rolling Submission of Bla to U.S. FDA for St-920 in Fabry Disease

THOMSON REUTERS
·
Mar 09

Sangamo Therapeutics: STAAR Study Demonstrated Positive Mean Annualized Egfr Slope at 52-Weeks Across All Dosed Patients

THOMSON REUTERS
·
Mar 09

What Sangamo Therapeutics (SGMO)'s Fabry Gene Therapy Progress And Equity Raise Means For Shareholders

Simply Wall St.
·
Feb 04

Sangamo Therapeutics stellt positive Phase-1/2-Studienergebnisse für Gentherapie bei Fabry-Krankheit vor

Reuters
·
Feb 04

Sangamo Therapeutics Begins Rolling BLA Submission to FDA for Fabry Disease Gene Therapy

Reuters
·
Feb 04

Sangamo says principal financial officer Prathyusha Duraibabu terminated

TIPRANKS
·
Feb 03

Sangamo names Nikunj Jain as interim CFO, principal financial officer

TIPRANKS
·
Feb 03

Sangamo prices 35.2M shares at 47.19c in underwritten offering

TIPRANKS
·
Feb 03

Sangamo Therapeutics Prices $25 Million Offering with Warrants and Share Rights

Reuters
·
Feb 03

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering

THOMSON REUTERS
·
Feb 03

BRIEF-Sangamo Therapeutics Inc - On Feb 2, Prathyusha Duraibabu Terminated As Principal Financial Officer - SEC Filing

Reuters
·
Feb 03

Sangamo Therapeutics Inc - on Feb 2, Prathyusha Duraibabu Terminated as Principal Financial Officer - SEC Filing

THOMSON REUTERS
·
Feb 03

Sangamo Therapeutics ernennt Nikunj Jain zum Interim-Finanzchef

Reuters
·
Feb 03

Sangamo Therapeutics Begins FDA Rolling Submission for ST-920 Gene Therapy in Fabry Disease

Reuters
·
Dec 18, 2025

Sangamo Therapeutics Inc - Expects to Complete Bla Submission by Q2 2026

THOMSON REUTERS
·
Dec 18, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, Boeing

Reuters
·
Dec 02, 2025

BUZZ-Sangamo jumps as US FDA fast-tracks drug for chronic nerve pain

Reuters
·
Dec 02, 2025

Sangamo Therapeutics Shares up 9.3% Premarket After Co Receives U.S. FDA Fast Track Designation for Its Experimental Treatment for Chronic Nerve Pain

THOMSON REUTERS
·
Dec 02, 2025